Curis (CRIS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
19 May, 2026Opening remarks and agenda
Meeting called to order with stockholders welcomed and agenda referenced on the web portal.
Inspector of Election appointed and meeting rules outlined, including Q&A process for proposals.
Directors, legal counsel, and auditors introduced as present telephonically.
Shareholder proposals
Five proposals presented: election of two Class 3 Directors, advisory vote on executive compensation, ratification of auditors, amendment to increase authorized shares, and adjournment authority.
Overview of voting outcomes
Both director nominees elected for three-year terms.
Executive compensation resolution approved by majority vote.
Ratification of PricewaterhouseCoopers LLP as auditors approved.
Amendment to increase authorized shares adopted.
Adjournment proposal approved.
Final vote results to be filed in Form 8-K within four business days.
Latest events from Curis
- Reverse stock split and adjournment proposals were both approved by majority vote.CRIS
EGM 202625 Jun 2026 - Emavusertib shows superior efficacy and safety in lymphoma and AML, with broad expansion plans.CRIS
Corporate presentation5 Jun 2026 - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.CRIS
Proxy filing5 Jun 2026 - Shareholders to vote on a reverse stock split to help maintain Nasdaq listing compliance.CRIS
Proxy filing22 May 2026 - Q1 2026 net loss was $24.2M; cash runway extends into H2 2027, but viability is uncertain.CRIS
Q1 202613 May 2026 - Shareholders will vote on director elections, executive pay, auditor ratification, and a share increase.CRIS
Proxy filing22 Apr 2026 - Shareholders will vote on director elections, executive pay, auditor ratification, and a major share increase.CRIS
Proxy filing10 Apr 2026 - Emavusertib delivers deep, durable responses in blood cancers and advances toward registrational trials.CRIS
Corporate presentation1 Apr 2026 - Q4 2025 net income surged on Erivedge sale; PCNSL and CLL studies drive future growth.CRIS
Q4 202520 Mar 2026